Nexella Pharma
Tokyo and Cambridge, UK, July 9, 2024 – Nxera Pharma K.K. (“Nxera”, TSE: 4565) will announce its financial results and business highlights for the six months ended June 30, 2024 on Friday, August 9, 2024.
The company will host a live webinar presentation on Friday, August 9, 2024 at 4:30pm Japan time (8:30am BST) featuring Chris Cargill, Representative Director, President and CEO, Matt Burns, CFO, President and Head of R&D, Nxera Pharma UK, and Satoshi Tanaka, President and Vice President, Nxera Pharma Japan.
The webinar is aimed at all existing and potential investors, as well as sell-side and buy-side analysts, and will consist of a presentation followed by a Q&A session. Please click here to pre-register and you will be provided with a link to access the webinar.
Presentation slides will be available to view in the Investor Relations section of the Company’s website by 4pm JST (8am BST) on August 9, 2024.
– end –
About Nxera Pharma
Nxera Pharma (formerly Sosei Heptares) is a technology-driven biopharmaceutical company pursuing novel specialty medicines to improve the lives of patients with unmet needs in Japan and around the world.
In addition to several products commercialized in Japan, we are advancing a broad pipeline of over 30 active programs, from discovery to late-stage clinical trials, both internally and in partnership with leading pharmaceutical and biotechnology companies. The pipeline is focused on addressing key unmet needs in some of the fastest growing areas of medicine, including neurology, gastroenterology and immunology, metabolic disorders and rare diseases, and leverages the power of our proprietary, industry-leading GPCR target structure-based drug discovery NxWave™ platform to provide a sustained source of best-in-class or first-to-market candidates.
Nxera employs over 350 talented people across key locations in Tokyo and Osaka (Japan), London, Cambridge (UK), Basel (Switzerland) and Seoul (Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).
For more information, visit www.nxera.life.
LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma
For further information:
Nexella Pharma
Kentaro Tahara, Vice President, Investor Relations and Corporate Strategy
Shinichiro Nishishita Vice President, Investor Relations and Head of Regulatory Disclosures
Maya Benison, Communications Manager
+81 (0)3 5210 3399 | +44 (0)1223 949390 | IR@Nxera.life
MEDiSTRAVA (for international media)
Mark Swallow, Fraser Hall, Erica Hollingsworth
+44 (0)203 928 6900 | Contact
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding product discovery, development and commercialization. A variety of risks could cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward-looking statements, including, but not limited to, adverse outcomes in clinical development programs, failure to obtain patent protection for inventions, commercial limitations imposed by patents owned or controlled by third parties, reliance on strategic collaboration partners to develop and commercialize products and services, difficulties or delays in obtaining regulatory approval to market products and services resulting from development efforts,
The story continues
“The Company is not responsible for any losses or damages that may arise from the use of this website or any of its products, including, but not limited to, the Company’s ability to provide services or products that meet its business objectives …
